Back to discover
Disease

Communicable Diseases

Late-stage therapeutic developmentExtensively researchedCooling momentum
139
Publications
4
Clinical trials
12
Related conditions
1
Related treatments
2
Related proteins
2026
Latest publication
Current focus
Therapeutic developmentVaccines biologyInflammation & immunity
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this disease.

Immunoengineering: An Emerging Field in Infectious Diseases.

Research2025-07-01The Journal of infectious diseases

Towards a 'people and nature' paradigm for biodiversity and infectious disease.

Research2025-01-09Philosophical transactions of the Royal Society of London. Series B, Biological sciences

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Executive briefingUpdating summary…Momentum: Moderate
Key developments
  • Active recent publication activity, including 1 notable finding.
Major developments
Activity timeline12

Research-associated treatments

Drugs and agents co-studied with this disease across the research literature — associative, not necessarily established treatments. Number shows shared papers.

Clinical trials

4 sponsors · 0 new · 0 completed in the last 12 months (net +0)

The current development programme across all trial phases.

Research activity

139 papers

Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.

Publications over time
20152026
Most influential
Recent publications
Major themes8
  • Communicable Diseases85
  • COVID-1922
  • Public Health8
  • Disease Outbreaks6
  • Climate Change5
  • Communicable Disease Control5
  • Developing Countries4
  • Endocarditis4
Leading journals6
  • Clinical infectious diseases : an official publication of the Infectious Diseases Society of America13
  • Frontiers in immunology5
  • Frontiers in public health5
  • Emerging infectious diseases4
  • PloS one4
  • Scientific reports4
Leading researchers8
  • Hoen B4
  • Liu Y4
  • Zhang Y4
  • Duval X3
  • Karchmer AW3
  • Li Y3
  • Selton-Suty C3
  • Barrat A2
Affiliations (unnormalised)6
  • School of Public Health9
  • Instituto de Salud Carlos III3
  • Northwestern University3
  • School of Global Health3
  • Université de Lorraine3
  • Université Paris Cité3

Disease biology

2 matches

Key proteins & gene products studied in this disease. Number shows shared papers.

Related conditions

12 matches

Diseases frequently studied alongside this one. Number shows shared papers.

Disease profile

A grounded synthesis of the condition — overview, causes, mechanism, risk factors and current standard of care.

Overview

Communicable diseases are illnesses caused by infectious agents or their toxins that can be transmitted directly or indirectly from an infected person, animal, vector, or the environment to a susceptible host. The literature grounding frames them as a broad category spanning epidemiology, diagnosis, immunology, mortality, transmission, etiology, genetics, and therapy.

Causes

They are caused by infectious agents or the toxins they produce. Transmission can occur through direct or indirect spread from infected individuals, animals, vectors, or inanimate environmental sources.

Pathophysiology

The biological basis centers on host-pathogen interactions and the host immune response to infection. The grounding highlights innate and adaptive immunity, cytokine signaling, and cytokine storm as important mechanisms in some infectious diseases, along with the role of host gene expression and immune maturation across the lifespan.

Risk factors

Risk is increased by exposure to infected individuals, animals, vectors, or contaminated environmental sources. The grounding also supports increased susceptibility with immature immune function in infancy and declining immune function in old age, as well as impaired immunity associated with protein or amino acid deficiency.

Current standard of care

Management is described at the level of diagnosis, drug therapy, and therapy rather than for a single disease entity. The grounding supports infectious-disease diagnosis using clinical metagenomics and treatment approaches that include antimicrobial or other drug therapy, with vaccines represented by COVID-19 vaccines and synthetic vaccine platforms in the literature.

AI-generated summary grounded in MeSH and 6 peer-reviewed sources. Informational only — not medical advice. Generated 2026-07-07.

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

An illness caused by an infectious agent or its toxins that occurs through the direct or indirect transmission of the infectious agent or its products from an infected individual or via an animal, vector or the inanimate environment to a susceptible animal or human host.

References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.